Table 4. Clinical details of Patients.
| Case | Gender | Age(Year) | SeizureType | MRI | Epilepsy syndrome | Anti-epileptic drug | |
| 1 | M | 15 | CPS | L Hippocampal Sclerosis | mTLE | Carbamazepine | |
| 2 | M | 16 | CPS | L Hippocampal Sclerosis | mTLE | Topiramate | |
| 3 | F | 15 | CPS | L Hippocampal Sclerosis | mTLE | Carbamazepine | |
| 4 | M | 17 | CPS | L Hippocampal Sclerosis | mTLE | Carbamazepine | |
| 5 | F | 30 | CPS | R Hippocampal Sclerosis | mTLE | None | |
| 6 | F | 22 | CPS | L Hippocampal Sclerosis | mTLE | None | |
| 7 | M | 10 | CPS | R Hippocampal Sclerosis | mTLE | None | |
| 8 | F | 11 | CPS | Normal | BECT | None | |
| 9 | F | 14 | CPS | R occipital lobeGray matter heterotopia | OLE | None | |
| 10 | F | 8 | CPS | Normal | BECT | Oxcarbazepine | |
| 11 | M | 35 | SPS | R frontal-parietal lobe lesion | FPLE | None | |
| 12 | M | 25 | CPS | L occipital lobeGray matter heterotopia | OLE | None | |
| 13 | M | 14 | CPS | L frontal lobeFCD | FLE | None | |
| 14 | M | 19 | SPS | Normal | FLE | None | |
| 15 | F | 9 | CPS | Normal | BECT | valproic acid | |
| 16 | M | 11 | CPS | Normal | BECT | None | |
SPS/CPS: Simple/Complex Partial Seizure; FCD: Focal Cortical Dysplasia; BECT: Benign Epilepsy of Childhood with Central-temporal spikes; mTLE: mesial temporal lobe epilepsy; OLE: occipital lobe epilepsy; FLE: frontal lobe epilepsy; R/L: right/left.